OBJECTIVES: To investigate whether a delay in nephroureterectomy for patients with transitional cell carcinoma of the upper urinary tract owing to ureteroscopic biopsy and/or laser tumor ablation affects postoperative disease status. METHODS: Of 155 patients diagnosed with upper tract transitional cell carcinoma at our institution from 1993 to 2003, 121 underwent nephroureterectomy. We compared the postoperative disease status of patients who underwent nephroureterectomy on the basis of positive cytology findings and filling defect on contrast imaging (no ureteroscopy; n = 34) to patients who underwent nephroureterectomy after ureteroscopic biopsy (n = 75) and patients who underwent nephroureterectomy after ureteroscopic biopsy and laser tumor ablation (n = 12). RESULTS: At a mean follow-up of 38.7 months, 29 (85.3%) of 34 patients who underwent nephroureterectomy on the basis of contrast imaging and urinary cytology alone were disease free compared with 61 (81.3%) of 75 patients who underwent ureteroscopic biopsy before nephroureterectomy (P = 0.18). The mean time from biopsy to nephroureterectomy for these 75 patients was 28 days, and the mean follow-up after nephroureterectomy was 40.1 months. Finally, 10 (83.3%) of 12 patients who underwent ureteroscopic biopsy and laser tumor ablation before nephroureterectomy were disease free at a mean follow-up of 37.2 months. The mean time from ureteroscopic biopsy to nephroureterectomy in this group was 196 days. No significant difference was found in the postoperative disease status between patients undergoing nephroureterectomy after ablation and those who proceeded to nephroureterectomy after endoscopic biopsy or those who did not undergo ureteroscopy before nephroureterectomy (P = 0.16). CONCLUSIONS: Ureteroscopy with biopsy and/or tumor ablation before nephroureterectomy did not adversely affect the postoperative disease status.
OBJECTIVES: To investigate whether a delay in nephroureterectomy for patients with transitional cell carcinoma of the upper urinary tract owing to ureteroscopic biopsy and/or laser tumor ablation affects postoperative disease status. METHODS: Of 155 patients diagnosed with upper tract transitional cell carcinoma at our institution from 1993 to 2003, 121 underwent nephroureterectomy. We compared the postoperative disease status of patients who underwent nephroureterectomy on the basis of positive cytology findings and filling defect on contrast imaging (no ureteroscopy; n = 34) to patients who underwent nephroureterectomy after ureteroscopic biopsy (n = 75) and patients who underwent nephroureterectomy after ureteroscopic biopsy and laser tumor ablation (n = 12). RESULTS: At a mean follow-up of 38.7 months, 29 (85.3%) of 34 patients who underwent nephroureterectomy on the basis of contrast imaging and urinary cytology alone were disease free compared with 61 (81.3%) of 75 patients who underwent ureteroscopic biopsy before nephroureterectomy (P = 0.18). The mean time from biopsy to nephroureterectomy for these 75 patients was 28 days, and the mean follow-up after nephroureterectomy was 40.1 months. Finally, 10 (83.3%) of 12 patients who underwent ureteroscopic biopsy and laser tumor ablation before nephroureterectomy were disease free at a mean follow-up of 37.2 months. The mean time from ureteroscopic biopsy to nephroureterectomy in this group was 196 days. No significant difference was found in the postoperative disease status between patients undergoing nephroureterectomy after ablation and those who proceeded to nephroureterectomy after endoscopic biopsy or those who did not undergo ureteroscopy before nephroureterectomy (P = 0.16). CONCLUSIONS: Ureteroscopy with biopsy and/or tumor ablation before nephroureterectomy did not adversely affect the postoperative disease status.
Authors: Andrea Orosa Andrada; Inés Laso García; Fernando Arias Fúnez; Francisco Donis Canet; Gemma Duque Ruiz; Victoria Gómez Dos Santos; Francisco Javier Burgos Revilla Journal: Can Urol Assoc J Date: 2017-07-11 Impact factor: 1.862
Authors: Debasish Sundi; Robert S Svatek; Vitaly Margulis; Christopher G Wood; Surena F Matin; Colin P Dinney; Ashish M Kamat Journal: Urol Oncol Date: 2010-09-25 Impact factor: 3.498
Authors: Alexander Sankin; Amy L Tin; Roy Mano; Michael Chevinsky; Chris Jakubowski; John P Sfakianos; Eugene K Cha; Alyssa Yee; Fara M Friedman; Daniel D Sjoberg; Behfar Ehdaie; Jonathan Coleman Journal: Urology Date: 2016-05-26 Impact factor: 2.649
Authors: Mariana Andozia Morini; Roberto Lodeiro Muller; Paulo César Barbosa de Castro Junior; Rafael José de Souza; Eliney Ferreira Faria Journal: World J Urol Date: 2018-03-16 Impact factor: 4.226
Authors: Laurent Nison; Morgan Rouprêt; Grégory Bozzini; Adil Ouzzane; François Audenet; Géraldine Pignot; Alain Ruffion; Jean-Nicolas Cornu; Sophie Hurel; Antoine Valeri; Mathieu Roumiguie; Thomas Polguer; Nicolas Hoarau; Olivier Mérigot de Treigny; Evanguelos Xylinas; Alexandre Matte; Stéphane Droupy; Pierre Olivier Fais; Aurélien Descazeaud; Pierre Colin Journal: World J Urol Date: 2012-10-16 Impact factor: 4.226